Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Vernon Bernardino has given his Buy rating due to a combination of factors, including promising preliminary results from Citius Pharmaceuticals’ ongoing clinical trial of Lymphir in combination with ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

The disappointing prostate cancer data follows two other failed trials reported last year, namely the KEYNOTE-921 study of Keytruda plus chemotherapy in metastatic castration-resistant prostate ...

Britain's Prince William said today that his wife Kate was doing "really well" and had been amazing in a year when she has undergone preventative chemotherapy for cancer. The British heir to the ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Just yesterday the SITC abstract was released with data from part one of our ARC-10 study which evaluated domvanalimab that's our anti PD1 antibody versus zim versus chemotherapy and first line PD ...

Here, the authors propose a model to predict chemotherapy response in breast cancer in real world clinical settings.

Findings seen in combination with chemotherapy following surgery in patients with curative intent. HealthDay News — Pembrolizumab plus chemotherapy improves disease-free survival (DFS ...